Outrage Over Dapagliflozin Withdrawal for Type 1 Diabetes in EU
The voluntary withdrawal of the type 1 diabetes indication for dapagliflozin in the EU by AstraZeneca has been branded as 'appalling' and 'devastating', with questions raised as to why it was pulled.
Source: medscape.com